In summary, reduced Aβ-42 levels in liver tissue from patients with MASLD might be due to limited Aβ-42 production because the expression of its rate-limiting enzyme BACE1 is decreased and UCHL1, a negative BACE1 regulator, is enhanced. This evidence concerns the gene BACE1 and metabolic dysfunction-associated steatotic liver disease.